Objective:

To highlight the limitations of traditional glaucoma treatment with topical drops and advocate for earlier interventional approaches to improve patient outcomes.

Approach:

• Interventional Glaucoma: Emphasizes the need for earlier intervention in glaucoma management to improve patient outcomes and quality of life.
• Challenges with Topical Therapy: Discusses the high rates of nonadherence to prescribed drop therapy and its consequences on disease progression.
• Minimally Invasive Glaucoma Surgery (MIGS): Introduces MIGS as a safer alternative to traditional surgery, allowing for earlier intervention.

Key Findings:

• 90% of patients do not adhere to their prescribed drop schedule according to the IRIS Registry Study.
• 50% of patients stop using their drops within 6 months as reported in the Market Scope Survey.
• Topical medications are effective but often lead to inconsistent IOP control, as noted in various studies.
• Minimally invasive procedures like selective laser trabeculoplasty (SLT) show promising results in maintaining IOP control with fewer complications, supported by the LiGHT trial.

Interpretation:

The reliance on topical drops for glaucoma management is problematic due to high nonadherence rates, leading to worse long-term outcomes. Early intervention with MIGS and sustained-release drug delivery systems may provide better control and quality of life for patients.

Limitations:

• The article does not provide specific data on the long-term outcomes of interventional glaucoma approaches compared to traditional methods, as noted in the IRIS Registry.
• Potential biases in the studies cited may affect the generalizability of the findings, as discussed in the Market Scope Survey.

Conclusion:

A shift towards interventional glaucoma strategies is necessary to address the challenges of adherence in glaucoma care.

Sources:

• IRIS Registry Study
• Market Scope Survey